Innovation and joint research centred on R&D
First written in FY2016. 16 of 30 entries say "Advanced", first in FY2017. Latest entry: FY2026.
25 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「The Group had 2,303 R&D personnel and total R&D expenses of ¥58.7 billion for the fiscal year,」
The Group disclosed 2,303 R&D personnel and R&D expenses of ¥58.7 billion, and reported results and progress including LEO satellite communications terminals, optical communications for lunar exploration, materials for medical devices, and automotive adoption of recycled PMMA materials. - FY2025AdvancedAnnual report
「The Group had 3,797 R&D personnel and total R&D expenses of ¥123.9 billion for the fiscal year,」
The Group disclosed 3,797 R&D personnel and R&D expenses of ¥123.9 billion, and reported results and progress including adoption of resin components for lunar rovers, a traceability system demonstration, resource-recycling carbon black, preparations for resubmitting ND0612, and demonstrations of CO2 capture equipment and ammonia-derived hydrogen production. - FY2024AdvancedAnnual report
「The Group had 3,867 R&D personnel and total R&D expenses of ¥121.6 billion for the fiscal year,」
The Group disclosed 3,867 R&D personnel and R&D expenses of ¥121.6 billion, and reported results including PFAS-free polycarbonate, C/SiC materials, biomass carbon-fibre prepreg, biodegradable biopolyester, and pharmaceutical approvals. - FY2024-Q3RestatedAnnual report
「Total R&D expenses for the cumulative third quarter of the current consolidated fiscal year were ¥89.0 billion.」
The Group continued its R&D activities and disclosed total R&D expenses of ¥89.0 billion for the nine months ended the third quarter of the fiscal year. - FY2024-Q2RestatedAnnual report
「Total R&D expenses for the cumulative second quarter of the current consolidated fiscal year were ¥59.1 billion.」
The Group continued its R&D activities and disclosed total R&D expenses of ¥59.1 billion for the six months ended the second quarter of the fiscal year. - FY2024-Q1AdvancedAnnual report
「The Group obtained approval in Switzerland in May 2023 for the edaravone oral suspension (development code: MT-1186) for the treatment of amyotrophic lateral sclerosis (ALS), marketed as RADICAVA® Oral Suspension. The product is already approved in the United States, Canada and Japan.」
In pharmaceutical R&D, the Group obtained Swiss approval in May 2023 for the edaravone oral suspension for ALS, expanding the number of countries in which it is approved. - FY2023AdvancedAnnual report
「The Group had 4,632 R&D personnel and total R&D expenses of ¥149.5 billion for the fiscal year,」
The Group disclosed 4,632 R&D personnel and R&D expenses of ¥149.5 billion, and reported results including next-generation communications materials, sleep sensors, chemical recycling, hydrogen combustion and CO2 capture equipment, and pharmaceutical approvals. - FY2023-Q3RestatedAnnual report
「Total R&D expenses for the cumulative third quarter of the current consolidated fiscal year were ¥116.1 billion.」
The Group continued its R&D activities and disclosed total R&D expenses of ¥116.1 billion for the nine months ended the third quarter of the fiscal year. - FY2023-Q2AdvancedAnnual report
「Approval in the United States was obtained in May 2022 for RADICAVA ORS® (development code: MT-1186; generic name: edaravone) for the indication of amyotrophic lateral sclerosis (ALS).」
The Group reported US approval of RADICAVA ORS, an ALS treatment, as a result for the six months ended the second quarter. - FY2023-Q1AdvancedAnnual report
「The Group obtained US approval in May 2022 for RADICAVA ORS® (development code: MT-1186; generic name: edaravone) for the treatment of amyotrophic lateral sclerosis (ALS). Edaravone had previously been administered only by intravenous infusion, but approval of this product enables oral administration, which is expected to reduce the burden on ALS patients, including injection pain and hospital visits for treatment. • The Group obtained approval in Japan in June 2022 for an additional indication for Canaglu® Tablets 100 mg (development code: TA-7284; generic name: canagliflozin hydrate) for chronic kidney disease associated with type 2 diabetes, excluding patients with end-stage renal failure or undergoing dialysis.」
In pharmaceutical R&D, the Group obtained US approval for RADICAVA ORS and approval in Japan for an additional indication for Canaglu Tablets for chronic kidney disease. - FY2022AdvancedAnnual report
「The Group had 4,720 R&D personnel, and total R&D expenses for the current consolidated fiscal year were ¥156.6 billion. R&D activities, results and expenses by business segment were as follows.」
The Group disclosed 4,720 R&D personnel and R&D expenses of ¥156.6 billion, and reported results including rapidly curing carbon-fibre prepreg, bio-based breathable films, GaN substrate demonstrations, ultra-low dielectric-loss films, approval of MT-2766, and Japanese approval of Dysval. - FY2022-Q2RestatedAnnual report
「Total R&D expenses for the six months ended the second quarter of the fiscal year were ¥73.9 billion.」
The Group continued its R&D activities and disclosed total R&D expenses of ¥73.9 billion for the six months ended the second quarter of the fiscal year. - FY2022-Q1AdvancedAnnual report
「Life Science Institute, Inc. began clinical trials in April 2021 for its Muse cell product CL2020 for acute respiratory distress syndrome associated with COVID-19, in addition to indications including acute myocardial infarction, cerebral infarction, epidermolysis bullosa, spinal cord injury, and amyotrophic lateral sclerosis (ALS).」
Clinical trials were initiated for the Muse cell product CL2020 in patients with acute respiratory distress syndrome associated with COVID-19. - FY2021AdvancedAnnual report
「The Group had 4,757 R&D personnel, and total R&D expenses for the current consolidated fiscal year were ¥126.1 billion. R&D activities, results and expenses by business segment were as follows.」
The Group disclosed 4,757 R&D personnel and R&D expenses of ¥126.1 billion, and reported concrete results including circular packaging materials, water purification equipment, oxygen applications, the start of the Phase 3 portion of a vaccine trial, and the start of clinical trials for Muse cell products. - FY2021-Q3RestatedAnnual report
「Total R&D expenses for the cumulative third quarter of the current consolidated fiscal year were ¥88.7 billion.」
The Group continued its R&D activities and disclosed total R&D expenses of ¥88.7 billion for the nine months ended the third quarter of fiscal 2020. - FY2020AdvancedAnnual report
「The Group had 4,774 R&D personnel and total R&D expenses of ¥133.4 billion for the fiscal year, with details of its research activities, results and R&D expenses by business division as follows.」
The Group disclosed 4,774 R&D personnel and R&D expenses of ¥133.4 billion, and reported the start of a global Phase 3 clinical trial for ND0612, the adoption of multiple products, and the development of new products. - FY2020-Q3RestatedAnnual report
「Total R&D expenses for the nine months ended the third quarter of the fiscal year were ¥96.4 billion.」
The Group continued its R&D activities and disclosed total R&D expenses of ¥96.4 billion for the nine months ended the third quarter of the fiscal year. - FY2020-Q2RestatedAnnual report
「Total R&D expenses for the cumulative second quarter of the current consolidated fiscal year were ¥65.9 billion.」
The Group continued its R&D activities and disclosed total R&D expenses of ¥65.9 billion for the six months ended the second quarter of fiscal 2019. - FY2020-Q1RestatedAnnual report
「Total R&D expenses for the cumulative first quarter of the current consolidated fiscal year were ¥32.6 billion.」
The Group continued its R&D activities and disclosed total R&D expenses of ¥32.6 billion for the first quarter of the fiscal year-to-date consolidated period. - FY2019AdvancedAnnual report
「The Group had 4,961 R&D personnel and total R&D expenses of ¥143.8 billion for the fiscal year, with details of its research activities, results and R&D expenses by business division as follows.」
The Group disclosed 4,961 R&D personnel and R&D expenses of ¥143.8 billion, and reported results including new grades of bio-engineering plastics, zeolite membranes for bioethanol production, conductive paste, a fully automated cell cryopreservation system, and the start of pharmaceutical clinical trials. - FY2019-Q3RestatedAnnual report
「Total R&D expenses for the cumulative third quarter of the current consolidated fiscal year were ¥103.6 billion.」
The Group continued its R&D activities and disclosed total R&D expenses of ¥103.6 billion for the nine months ended the third quarter of fiscal 2018. - FY2019-Q2RestatedAnnual report
「Total R&D expenses for the cumulative second quarter of the current consolidated fiscal year were ¥67.3 billion.」
The Group continued its R&D activities and disclosed total R&D expenses of ¥67.3 billion for the six months ended the second quarter of the fiscal year. - FY2018AdvancedAnnual report
「The Group had 4,843 R&D personnel and total R&D expenses of ¥138.8 billion for the fiscal year, with details of its research activities, results and R&D expenses by business division as follows.」
The Group disclosed 4,843 R&D personnel and R&D expenses of ¥138.8 billion, and reported concrete results including adoption of carbon-fibre-reinforced plastic in Audi vehicles, the launch of IoT water purifiers, and the start of Phase 2/3 and Phase 3 pharmaceutical trials. - FY2018-Q3AdvancedAnnual report
「In November 2017, Tanabe Mitsubishi Pharma Co., Ltd. entered into a share transfer agreement with Steric Regenerative Medicine Institute Co., Ltd., which conducts pharmaceutical research and development, to acquire the company. The contractual position of Tanabe Mitsubishi Pharma Co., Ltd. under the agreement, together with all rights and obligations arising from it, was transferred to MT Star Co., Ltd., its consolidated subsidiary, in November of the same year.」
The Group entered into an agreement to acquire STERIC Institute of Regenerative Medicine, which conducts pharmaceutical research and development, marking concrete progress toward expanding its R&D platform. - FY2018-Q2RestatedAnnual report
「Total R&D expenses for the first six months of the fiscal year were ¥66.4 billion.」
The Group continued its R&D activities and disclosed total R&D expenses of ¥66.4 billion for the six months ended the second quarter of the fiscal year. - FY2018-Q1AdvancedAnnual report
「The Group is currently advancing development centred on ND0612, a treatment for Parkinson’s disease that is moving into Phase 3 in the United States and Europe and is expected to launch in fiscal 2019.」
ND0612, the subject of the acquisition of NeuroDerm, had entered Phase 3 development in the United States and Europe and was expected to launch in fiscal 2019. - FY2017AdvancedAnnual report
「In addition to conducting proprietary R&D activities at each company, the Group is actively pursuing the development of new technologies and improvements to existing technologies by cooperating with one another and strengthening collaboration through close exchanges of information on technologies and markets among Group companies, joint research, and the commissioning and undertaking of R&D activities, as well as by actively conducting joint R&D with companies and other parties outside the Group.」
The Group disclosed 4,883 R&D personnel and R&D expenses of ¥126.3 billion, and reported results including the launch of product sales, adoption in customer products, and progress in CNF patent licensing with Kyoto University. - FY2017-Q3RestatedAnnual report
「Total R&D expenses for the first 9 months of the fiscal year were ¥89.4 billion.」
The Group continued its R&D activities and disclosed total R&D expenses of ¥89.4 billion for the nine months ended the third quarter of the fiscal year. - FY2017-Q1RestatedAnnual report
「Total R&D expenses for the first quarter of the fiscal year were ¥28.8 billion.」
The Group continued its R&D activities and disclosed total R&D expenses of ¥28.8 billion for the first quarter of the fiscal year-to-date consolidated period. - FY2016First statedAnnual report
「In addition to conducting proprietary R&D activities at each company, the Group is actively pursuing the development of new technologies and improvements to existing technologies by cooperating with one another and strengthening collaboration through close exchanges of information on technologies and markets among Group companies, joint research, and the commissioning and undertaking of R&D activities, as well as by actively conducting joint R&D with companies and other parties outside the Group.」
The Group disclosed 5,040 R&D personnel and R&D expenses of ¥138.3 billion for the fiscal year, and uses joint research with internal and external parties as a means of advancing R&D.